MedPath

Altamira Therapeutics AG

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
$2.9M
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

No trials found

News

Altamira Therapeutics Partners with Undisclosed Company to Advance Circular RNA Delivery Platform

Altamira Therapeutics has entered into a collaboration agreement with an undisclosed company to evaluate its CycloPhore platform for delivering circular RNA payloads.

Altamira Therapeutics Partners with Radiopharmaceutical Company to Enhance Cancer Treatment Targeting

Altamira Therapeutics has entered into a collaboration agreement with an undisclosed radiopharmaceutical company to evaluate the use of its proprietary RNA delivery platform for enhanced cancer targeting.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.